For the later coming in global industry, low-end entry, economies of scale and cost advantages are tools for rapid industry growth in API, China. After 20 years of rapid development of interfaces and pharmaceutical intermediates, as the largest suppliers in the world, China has built its strong international position.

A global economic recovery and the pharmaceutical market is the increased demand, import and export of Chinese medicine irinotecan to achieve a quicker recovery. Pharmaceutical importers of raw materials in Europe and the United States attaches great importance to long-term operation, more attention to brand and reputation, and Indian traders worried about the price of the product is, of course, some of which China lacks awareness of new business and small business opportunity. Business of penicillin production in China is transferred to the manufacturing, processing in-depth product of penicillin, the main export markets has grown significantly in Spain. Indonesia, Germany, Japan, exports increased by 217% 63%, 528% and 361%.

Today, the rapid development of the generics of the same drug in a large-scale drug brand after the elevation is 4.5 enterprises in production, will inevitably lead to prices of patented drugs declined, and demand for these resources, the largest amounts. In the coming years the demand for the volume of generic drugs, approximately 15 percent compound annual growth rate, which is also a great opportunity for growth that the best generals in the world of pharmaceutical raw materials producing countries of China. His addition, many of the characteristics of raw materials for drug costs and the price, the advantage of scale, high market share in the international market, other countries can not be replaced in short-term properties of the mass production of medicines for calls.

With increasing competition in the sums of the first major pharmaceutical companies in recent years, signs of diversification in a series of committee business and industrial markets custom processing. The major pharmaceutical companies in China have begun to fine quality products of mass production low-end temporary change in the subsequent expansion of the transmission and distribution facilities in-depth treatment to save. At the same time, Chinese companies have also begun with international quality certificates to receive API has improved considerably.

With the benefit that multinational pharmaceutical raw materials suppliers will transfer manufacturing activities to China and basing on the Chinese pharmaceutical stocks, generic prosperity of China enjoys an important position. Currently, the main raw materials for pharmaceutical companies increase the strength of new product launches and market culture. It absolutely provides an opportunity for pharmaceutical raw materials industry. After years of unremitting efforts, Chinese companies pharmaceutical raw materials should seize the historic opportunity for the industry  and accelerate sustainable and healthy development in production and sale of pharmaceutical raw.Source:http://www.cospcn.com